---
document_datetime: 2024-03-05 15:56:13
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-tad-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: clopidogrel-tad-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.9203537
conversion_datetime: 2025-12-30 22:29:31.860245
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel TAD

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0039/G            | This was an application for a group of variations. | 21/12/2023                          | 12/01/2024                                  | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |             | new additional data   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IB/0038 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                          | 08/07/2022 | 04/07/2023 | SmPC and PL |                       |
| IB/0037 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                  | 04/10/2021 | 28/10/2021 | SmPC and PL | the MAH               |
| IB/0036 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                          | 26/04/2021 | 10/05/2021 | SmPC and PL |                       |
| IB/0035 | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                     | 01/12/2020 | 10/05/2021 | SmPC,       |                       |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                   |            |            | Labelling and PL                 |         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------|
| IB/0034   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                         | 13/03/2020 | 02/06/2020 | SmPC and PL                      | the MAH |
| IB/0033   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/09/2019 | 02/06/2020 | SmPC, Annex II, Labelling and PL |         |
| IB/0032/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 05/06/2019 | 02/06/2020 | SmPC, Labelling and PL           |         |

<div style=\"page-break-after: always\"></div>

|           | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                               | 05/04/2019   | 02/06/2020   | PL                     | N/0031                |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------|
| IB/0030   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                   | 10/05/2018   | 06/06/2019   | SmPC, Labelling and PL |                       |
| IA/0029/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch place                             | 22/02/2018   | n/a          |                        | control/testing takes |
| IB/0028/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following | 22/06/2017   | 19/07/2017   | SmPC, Labelling and PL |                       |

<div style=\"page-break-after: always\"></div>

|           | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   |            |            |                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|
| IB/0027/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/12/2015 | 27/05/2016 | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                | 10/06/2015 | 27/05/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/07/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0022            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/03/2014 | 22/05/2014 |             | The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. The MAH has submitted an Addendum to Clinical Overview (ACO) to provide details of the efficacy and safety of Clopidogrel TAD since its approval. In the CHMP's view the provided data do not change the overall knowledge about the beneficial effect and safety profile of clopidogrel when used in the approved indications. |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | The beneficial effect of Clopidogrel TAD remains in line with that of the originator product (Plavix), and is considered positive.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 14/05/2014 | 27/05/2015 | SmPC and PL |                                                                                                                                      |
| IB/0020/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                        | 31/01/2014 | n/a        |             |                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0023   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                         | 20/01/2014   | 22/05/2014   | SmPC and PL                      |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------|
| IB/0021/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 14/11/2013   | 22/05/2014   | SmPC                             | the MAH   |
| IB/0018/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                            | 21/08/2013   | 22/05/2014   | SmPC, Annex II, Labelling and PL | C.I.2.a - |

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following of the same change for the reference - Implementation of change(s) for which NO additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                             |            |            |             | assessment product new   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------|
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/11/2012 | 22/05/2014 | PL          |                          |
| IB/0016 | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                              | 07/09/2012 | n/a        |             |                          |
|         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch | 07/03/2012 | n/a        |             | IB/0015/G size           |
| IB/0014 | B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/03/2012 | 12/09/2012 | SmPC and PL |                          |
| IB/0012 | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/08/2011 | n/a        | SmPC and PL |                          |

<div style=\"page-break-after: always\"></div>

|         | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                   |            |     |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                      | 08/08/2011 | n/a | SmPC                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0013 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 26/07/2011 | n/a |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0009 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 28/04/2011 | n/a | SmPC, Annex II and PL | To amend the SPC and PL to update section 4.2 \"posology and method of administration\", 4.4 \"Special warnings and precaution for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genertic variation of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitors (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3). In addition annex II has been updated to remove the version number and date for the DDPS system in line with the procedural anouncements in October and November 2010. Furthermore corrections were made to the list of local |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                              |            |     |             | representatives for Estonia, Latvia, Poland and Malta.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------------------------------------------------|
| IA/0010   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                | 14/04/2011 | n/a |             |                                                          |
| IB/0008   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                               | 06/08/2010 | n/a | SmPC and PL |                                                          |
| IA/0007   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                           | 05/07/2010 | n/a |             |                                                          |
| IB/0005/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 08/06/2010 | n/a |             |                                                          |
| IA/0006   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                               | 26/05/2010 | n/a |             |                                                          |
| N/0003    | Addition of contact details of local representatives in Portugal, Greece and Ireland in Annex IIIB (Package                                                                                                                                                                                  | 28/01/2010 | n/a | PL          |                                                          |

<div style=\"page-break-after: always\"></div>

|         | Leaflet). Furthermore, removal of second telephone number of Greek representative together with removal of date after the statement in Annex IIIB 'This leaflet was last approved in Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   |            |            |             |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| II/0001 | addition of alternative manufcture for an intermediate and change in manufacturer process of intermediate Quality changes                                                                                                                                                               | 17/12/2009 | 08/01/2010 |             |
| IB/0002 | IB_18_Replacement of an excipient with a comparable excipient                                                                                                                                                                                                                           | 23/12/2009 | n/a        | SmPC and PL |